Australian biotech company Immutep (ASX: IMM, NASDAQ: IMMP) has delivered impressive Phase I clinical trial results for its TACTI-mel trial which has observed significant tumour size shrinkage in the majority of trial patients over the 12 month trial period. The trials tested 24 patients with melanoma which were located in areas not capable of being
Read MoreSufferers of skin conditions like acne, psoriasis and dermatitis could soon have effective cannabinoid therapeutics thanks to Botanix (ASX:BOT) and their synthetic cannabinoid trials. Presenting at the International Cannabinoid Derived Pharmaceuticals (iCDP) Summit in Boston, the presentation titled Fact or Fiction, highlighted the effectiveness seen in their recently completed clinical trials to treat acne, and
Read MoreMed-tech developer ResApp Health (ASX: RAP) has received certification from European regulators for the world’s first smartphone-based respiratory diagnostics test. ResAppDx-EU is a mobile app which can be used by medical clinicians to diagnose respiratory conditions including tract disease, croup, pneumonia, asthma and bronchiolitis. “We are very excited about receiving our first regulatory approval for
Read MoreWith the average person’s life expectancy rising, Alzheimer’s disease is emerging as a major health concern which can have devastating effects on an individual’s cognitive function. It leads to progressive loss of brain cells which later leads to loss of memory and has become a global menace, costing the world over US$818 billion in treatment
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.